



GWG TRAN Recommendations

Gil R Sambrano

Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine

TRANSFORMING

*medicine
lives
futures*

October 18, 2018

Funding Opportunities



DISCOVERY



TRANSLATION



CLINICAL

New
Idea



Single Product
Candidate



Pre-IND Meeting
or Equivalent



Approved
Therapy



Every Moment Counts | Don't Stop Now

CIRM Translation Research Program (TRAN)

Objective


To support promising stem cell-based projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use.

What qualifies for TRAN?

Projects that propose a candidate:

- Therapeutic (TRAN 1)
- Diagnostic (TRAN 2)
- Medical device (TRAN 3)
- Tool (TRAN4)

CIRM Translation Program



Every Moment Counts | Don't Stop Now

Review Criteria

- ✓ Does the project hold the necessary significance and potential for impact?
- ✓ Is the rationale sound?
- ✓ Is the project well planned and designed?
- ✓ Is the project feasible?

Scoring System

- **Score of “85-100”**

Recommended for funding, if funds are available

- **Score of “1-84”**

Not recommended for funding

Applications are scored by all scientific members of the GWG with no conflict.

The **median** of all individual GWG scores determines final score.

GWG Recommendations

| | Number of Apps | Total Applicant Request | Funds Available |
|--|----------------|-------------------------|-----------------|
| Recommended for funding Score 85-100 | 3 | \$13,478,286 | \$15,842,345 |
| Not recommended for funding Score 1-84 | 9 | | |

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.

Overview of Recommended Applications

TRAN1-11265

TITLE: Clinical Translation of Autologous Regenerative Cell Therapy for Blindness

DISEASE INDICATION: Retinal diseases

PRODUCT TYPE: Cell therapy

APPROACH: Autologous iPSC-derived retinal progenitor cell transplant

TRAN1-11259

TITLE: Developing engineered autologous leukemia vaccines to target residual leukemic stem cells

DISEASE INDICATION: Acute myelogenous leukemia (AML)

PRODUCT TYPE: Biologic

APPROACH: Autologous genetically-modified AML vaccine targeting cancer stem cells

TRAN1-11300

TITLE: A purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration

DISEASE INDICATION: Age-related macular degeneration

PRODUCT TYPE: Cell therapy

APPROACH: Allogeneic neural stem cell transplant